IL3RA Antibody

說明書

中文名稱：

IL3RA兔多克隆抗體
貨號：

CSB-PA925610
規格：

￥1100
圖片：
The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using CSB-PA925610(IL3RA Antibody) at dilution 1/35, on the right is treated with synthetic peptide. (Original magnification: ×200)

Gel: 8%SDS-PAGE,Lysate: 40 μg,,Primary antibody: CSB-PA925610(IL3RA Antibody) at dilution 1/200 dilution,Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution,Exposure time: 30 seconds
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

P26951
基因名：

IL3RA
別名：

IL3RA; IL3R; Interleukin-3 receptor subunit alpha; IL-3 receptor subunit alpha; IL-3R subunit alpha; IL-3R-alpha; IL-3RA; CD antigen CD123
宿主：

Rabbit
反應種屬：

Human,Mouse
免疫原：

Synthetic peptide of Human IL3RA
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

Antigen affinity purification
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
產品提供形式：

Liquid
應用范圍：

ELISA,WB,IHC

推薦稀釋比：

Application	Recommended Dilution
ELISA	1:2000-1:5000
WB	1:500-1:2000
IHC	1:25-1:100

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

This is a receptor for interleukin-3.
基因功能參考文獻：
1. Family-based whole genome analysis of a family with hereditary pulmonary alveolar proteinosis revealed a homozygous deletion that disrupts CSF2RA, CRLF2, and IL3RA gene in the pseudoautosomal region of the X chromosome in the affected child and one of asymptomatic siblings. PMID: 28233860
2. Our data define the mechanisms by which SL-101 targets acute myeloid leukemia (AML)and warrant further investigation of the clinical application of SL-101 and other CD123-targeting strategies in AML. PMID: 28096272
3. Data show that the N-terminal domain (NTD) of interleukin 3 receptor subunit alpha (IL3Ralpha) exhibits exquisite flexibility and a dynamic transition from a high to a low mobility state upon cytokine binding. PMID: 29374162
4. the oncogenic events of FLT3/ITD happen at a cell stage possessing CD123 PMID: 27465508
5. Data indicate that CD123 was preferentially expressed among CD33/CD117-positive precursor-T-acute lymphoblastic leukemia (T-ALL). PMID: 26474588
6. CD123 positivity represents a marker that can facilitate identification of the early T-cell precursor leukemia subtype, but the lack of sensitivity by immunohistochemistry limits the diagnostic utility. PMID: 25906118
7. CD123 expression is associated with systemic mastocytosis. PMID: 26678095
8. Human BDCA2+CD123+CD56+ dendritic cells (DCs) related to blastic plasmacytoid dendritic cell neoplasm represent a unique myeloid DC subset. PMID: 25779340
9. CD96 and CD123 are expressed in bone marrow cells of patients with myelodysplastic syndromes PMID: 26642704
10. High interleukin-3 receptor alpha is associated with blastic plasmacytoid dendritic cell neoplasm. PMID: 25381130
11. High CD123 expression is associated with systemic mastocytosis. PMID: 25640886
12. CD123+ plasmacytoid dendritic cells contribute to the sarcoidal granulomas associated with injected permanent fillers. PMID: 25406851
13. 87.8% of AMLs express CD33. Additionally, 9.4% of AMLs express CD123 without concomitant CD33 expression. PMID: 24927407
14. Increases in CD34(+)CD38(-)CD123(+) cells may reflect malignant clonal cells with aberrant differentiation, overproliferation, and decreased apoptosis in myelodysplastic syndrome, which were similar to acute myeloid leukemia. PMID: 24846193
15. In the present study we analyzed the expression of four cell surface antigens relevant to human hematopoiesis-CD90, CD96, CD117, and CD123-in bone marrow from pediatric acute myeloid leukemia patients and normal control subjects. PMID: 24751333
16. We conclude the hMICL/CD123-based MFC assay is a promising MRD tool in AML. PMID: 24152218
17. Results suggest that CD123 results suggest that CD123 chimeric antigen receptors (CARs) T cells are a promising immunotherapy for the treatment of high-risk acute myeloid leukemia (AML). PMID: 24030378
18. CD123 is a useful immunohistochemical marker to facilitate diagnosis of acute graft-versus-host disease in colon. PMID: 23791208
19. CD123 expression in acute myeloid leukemia is associated with underlying FLT3 and NPM1 mutations. PMID: 22914610
20. We recommend immunohistochemical analyses for CD123, CD56 and CD4 inblastic plasmacytoid dendritic cell neoplasm patients, particularly in cases where the initial bone marrow study indicates normal morphology. PMID: 23470050
21. we report that IL3 receptor alpha (IL3Ralpha) and NOTCH play integral roles in the host cell type-specific regulation of PROX1 by Kaposi sarcoma herpes virus PMID: 22719258
22. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia PMID: 21933861
23. The pattern of CD123 staining can be a useful feature to distinguish hypertrophic lupus erythematosus, squamous cell carcinoma and hypertrophic actinic keratosis. PMID: 21955314
24. These findings support the usefulness of CD123 and CD103 to aid in the differential diagnosis of B-cell lymphoproliferative disorders PMID: 21917686
25. assessment of CD123 expression is useful for supporting the diagnosis of classical Hodgkin lymphoma PMID: 20809502
26. Over expression of IL-3Ralpha and truncated mutation of hbetac may be involved in proliferation and differentiation block in NB4 cells. PMID: 21176354
27. Interleukin 3 receptor alpha is a cell-surface marker present on leukemia-initiating cells of patients with Fanconi anemia-acute myeloid leukemia, and may be a promising therapeutic target for these patients. PMID: 21330473
28. CD123 was highly expressed in the bone marrow of the patients with myelodysplastic syndrome, significantly correlated with the proportion of bone marrow blasts, and thus might be the marker of MDS malignant clone. PMID: 20819538
29. Expression of dendritic cell markers CD11c/BDCA-1 and CD123/BDCA-2 in coronary artery disease upon activation in whole blood. PMID: 20888334
30. Data show high expression of CD86 and CD11C, moderate expression of CD1a and CD123, low levels of CD83 on dendritic cells after induction by GM-CSF and IL-4. PMID: 19257981
31. Elevated expression in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis PMID: 12351411
32. Bioinformatic study of IL-3 Ralpha & GM Ralpha subunits found a tripeptide sequence near the conserved proline-rich domain which was a key difference between them. Cross-exchange of equivalent subunits altered function compared to wild-type receptors. PMID: 12384414
33. Analysis of the 5' promoter of the hIL-3Ra gene. PMID: 12504125
34. IL-3Ralpha mRNA is upregulated by IL-3, IL-5, and GM-CSF in human eosinophils PMID: 12943658
35. IL-3 receptor activation is not essential for BCR-ABL-induced myeloproliferative diseases PMID: 14500898
36. REVIEWS overexpression of the IL-3Ralpha chain as one of the mechanisms contributing to the development of a highly malignant leukemic phenotype and evidence that IL-3Ralpha is a marker of leukemic stem cells PMID: 14671644
37. Therefore, these data provide strong evidence that integrin-dependent STAT5A activation controls IL-3-mediated proliferation. PMID: 15795318
38. role in modulating tumor neovascularization in conjunction with VEGFR (KDR) PMID: 16007196
39. Sequencing of interleukin 3 receptor alpha in an independent case-control cohort revealed both common intronic haplotypes and several novel, rare missense variants associated with schizophrenia. PMID: 17522711
40. variants in the gene coding for its receptor (IL-23R) are strongly associated with Crohn's disease PMID: 18047539
41. A small but significant contribution of the IL3RA polymorphism to susceptibility to schizophrenia, suggesting that the IL3 pathway may be involved in schizophrenia. PMID: 18547720
42. CD123+ MDCs were an early-stage immature DC subset, with a significant tumor-inhibiting activity partially via involvement of enhanced cytoplasmic TRAIL. PMID: 18555589
43. our family-based association study revealed a small but significant contribution of the IL3RA variants to susceptibility to schizophrenia in a Chinese population (Han) PMID: 19281803
44. overexpression of CD123 is an aberrant phenotype present in a subset of precursor-B ALL with hyperdiploid genotype PMID: 19454491
45. Progression of cutaneous squamous cell carcinoma in immunosuppressed patients is associated with reduced CD123+ and FOXP3+ cells in the perineoplastic inflammatory infiltrate. PMID: 19614769
46. the less mature hematogones (dim CD45+) that express CD34 lack CD123 expression, whereas the more mature hematogones (moderate CD45+) lack CD34 but always express CD123. PMID: 19762535
顯示更多

收起更多
亞細胞定位：

Membrane; Single-pass type I membrane protein.
蛋白家族：

Type I cytokine receptor family, Type 5 subfamily
數據庫鏈接：

HGNC: 6012

OMIM: 308385

KEGG: hsa:3563

STRING: 9606.ENSP00000327890

UniGene: Hs.632790

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human